Literature DB >> 2920007

Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa.

F A Ofosu1, J Hirsh, C T Esmon, G J Modi, L M Smith, N Anvari, M R Buchanan, J W Fenton, M A Blajchman.   

Abstract

We have proposed previously that the steps in coagulation most sensitive to inhibition by heparin are the thrombin-dependent amplification reactions, and that prothrombinase is formed in heparinized plasma only after Factor Xa activates Factor VIII and Factor V. These propositions were based on the demonstration that both heparin and Phe-Pro-Arg-CH2Cl completely inhibited 125I-prothrombin activation for up to 60 s when contact-activated plasma (CAP) was replenished with Ca2+. Furthermore, the addition of thrombin to CAP before heparin or Phe-Pro-Arg-CH2Cl completely reversed their inhibitory effects. Additional support for the above hypotheses is provided in this study by demonstrating that, when the activity of thrombin is suppressed by heparin (indirectly) or by Phe-Pro-Arg-CH2Cl (directly), exogenous Factor Xa reverses the ability of these two agents to inhibit prothrombin activation. Prothrombin activation was initiated by adding Factor Xa (1 nM) or thrombin (1 or 10 nM) simultaneously with CaCl2 to CAP. In the absence of heparin or Phe-Pro-Arg-CH2Cl, prothrombin activation was seen 15 s later in either case. Heparin failed to delay, and Phe-Pro-Arg-CH2Cl delayed for 15 s, prothrombin activation in CAP supplemented with Factor Xa. In contrast, heparin and Phe-Pro-Arg-CH2Cl completely inhibited prothrombin activation for at least 45 s in CAP supplemented with 1 nM-thrombin. Heparin failed to delay prothrombin activation in CAP supplemented with 10 nM-thrombin, whereas Phe-Pro-Arg-CH2Cl completely inhibited prothrombin activation in this plasma for 45 s. These results suggest that in CAP: (1) Factor Xa can effectively activate Factor VIII and Factor V when the proteolytic activity of thrombin is suppressed; (2) heparin-antithrombin III is less able to inhibit Factor Xa than thrombin; (3) suppression of the thrombin-dependent amplification reactions is the primary anticoagulant effect of heparin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920007      PMCID: PMC1135548          DOI: 10.1042/bj2570143

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.

Authors:  F A Ofosu; G J Modi; M A Blajchman; M R Buchanan; E A Johnson
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

2.  The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity.

Authors:  C T Esmon
Journal:  J Biol Chem       Date:  1979-02-10       Impact factor: 5.157

3.  The role of phospholipid and factor VIIIa in the activation of bovine factor X.

Authors:  G van Dieijen; G Tans; J Rosing; H C Hemker
Journal:  J Biol Chem       Date:  1981-04-10       Impact factor: 5.157

4.  The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin.

Authors:  R E Jordan; G M Oosta; W T Gardner; R D Rosenberg
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

5.  Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography.

Authors:  H Hoogendoorn; A Cerskus; F Ofosu; M Blajchman; J Hirsh
Journal:  Thromb Res       Date:  1980-10-01       Impact factor: 3.944

6.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin.

Authors:  C Kettner; E Shaw
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

7.  The activation of factor V by factor Xa or alpha-chymotrypsin and comparison with thrombin and RVV-V action. An improved factor V isolation procedure.

Authors:  C M Smith; D J Hanahan
Journal:  Biochemistry       Date:  1976-05-04       Impact factor: 3.162

8.  Thrombin-catalyzed activation of single chain bovine factor V.

Authors:  M E Nesheim; K G Mann
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

9.  The role of phospholipids and factor Va in the prothrombinase complex.

Authors:  J Rosing; G Tans; J W Govers-Riemslag; R F Zwaal; H C Hemker
Journal:  J Biol Chem       Date:  1980-01-10       Impact factor: 5.157

10.  Preparation and properties of bovine factor VIII (antihemophilic factor).

Authors:  G A Vehar; E W Davie
Journal:  Biochemistry       Date:  1980-02-05       Impact factor: 3.162

View more
  9 in total

1.  Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes.

Authors:  S M Jafri
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

2.  Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.

Authors:  X J Yang; M A Blajchman; S Craven; L M Smith; N Anvari; F A Ofosu
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

3.  Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.

Authors:  F A Ofosu; J W Fenton; J Maraganore; M A Blajchman; X Yang; L Smith; N Anvari; M R Buchanan; J Hirsh
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

4.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

Review 5.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

6.  Anticoagulation after intracoronary stent insertion.

Authors:  M J Brack; P J Hubner; A H Gershlick
Journal:  Br Heart J       Date:  1994-09

Review 7.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

8.  Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.

Authors:  Ruwan Gunaratne; Shekhar Kumar; James W Frederiksen; Steven Stayrook; Jens L Lohrmann; Kay Perry; Kristin M Bompiani; Charlene V Chabata; Nabil K Thalji; Michelle D Ho; Gowthami Arepally; Rodney M Camire; Sriram Krishnaswamy; Bruce A Sullenger
Journal:  Nat Biotechnol       Date:  2018-06-04       Impact factor: 54.908

9.  Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.

Authors:  Hooi Ching Lim; Hinke A B Multhaupt; John R Couchman
Journal:  Mol Cancer       Date:  2015-01-27       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.